AVACTA GROUP PLC - Preliminary Results for the year ended December 31, 2025 episode artwork

EPISODE · May 19, 2026

AVACTA GROUP PLC - Preliminary Results for the year ended December 31, 2025

from Investor Meet Podcast - AI · host Investor Meet Company

Today's podcast explores Avacta Group PLC's fiscal 2025 preliminary results, focusing on their innovative cancer therapy approach using a two amino acid cap. This method aims to transform targeted cancer treatments by bypassing traditional chemotherapy's harmful effects. Avacta's precision platform targets the FAP enzyme found in 90% of solid tumors, allowing for significant drug concentration directly within the tumor while minimizing damage to healthy tissues. Clinical data from their Gen 1 program, AVA 6000, shows promising results without systemic toxicity, leading to an increased lifetime maximum dose limit for patients. The company is now aggressively pursuing US-based Gen 2 trials, positioned for potential transformative advances in the coming 9 to 12 months.

Episode metadata supplied by the publisher feed · Published May 19, 2026

Embed this episode

Ready to play

AVACTA GROUP PLC - Preliminary Results for the year ended December 31, 2025

0:00 0:00

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

When was this Investor Meet Podcast - AI episode published?

This episode was published on May 19, 2026.

Can I download this Investor Meet Podcast - AI episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!